Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents [Hematologic Malignancy]
Purpose This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion–dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Patients and Methods In total, 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The primary end point was the rate of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Santini, Almeida, Giagounidis, Gropper, Jonasova, Vey, Mufti, Buckstein, Mittelman, Platzbecker, Shpilberg, Ram, del Canizo, Gattermann, Ozawa, Risueno, MacBeth, Zhong, Seguy, Hoenekopp, Beach, Fenaux Tags: Chemotherapy Hematologic Malignancy Source Type: research

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion First-line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gettinger, Rizvi, Chow, Borghaei, Brahmer, Ready, Gerber, Shepherd, Antonia, Goldman, Juergens, Laurie, Nathan, Shen, Harbison, Hellmann Tags: Chemotherapy Thoracic Oncology Source Type: research

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion The safety profile of nivolumab plus PT-DC was consistent with that expected for individual agents; however, treatment discontinuation related to AEs was greater with the combination. Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Rizvi, Hellmann, Brahmer, Juergens, Borghaei, Gettinger, Chow, Gerber, Laurie, Goldman, Shepherd, Chen, Shen, Nathan, Harbison, Antonia Tags: Chemotherapy Thoracic Oncology Source Type: research

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer [Rapid Communication]
Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent the development of the current standard therapy for estrogen receptor–positive advanced breast cancer. Materials and Methods In a prospective-retrospective analysis, we assessed ESR1 mutations in available archived baseline plasma from the SoFEA (Study of Faslodex Versus Exemestane With or Without Arimidex) trial, which compared exemestane with fulvestrant-containing regimens in patients...
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Fribbens, OLeary, Kilburn, Hrebien, Garcia-Murillas, Beaney, Cristofanilli, Andre, Loi, Loibl, Jiang, Bartlett, Koehler, Dowsett, Bliss, Johnston, Turner Tags: Combined Modality, Hormonal Therapy, Translational Oncology, Rapid Communications Source Type: research

Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Alumkal, Beer Tags: Clinical Trials, Systemic Therapy EDITORIALS Source Type: research

Long Days Journey Into Night for Lower-Risk Myelodysplastic Syndromes [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Sekeres Tags: Chemotherapy EDITORIALS Source Type: research

Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gainor Tags: Translational Oncology, Chemotherapy EDITORIALS Source Type: research

Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Lauring, Wolff Tags: Hormonal Therapy, Translational Oncology, Cancer Biomarkers EDITORIALS Source Type: research

2016 ASCO Presidential Address: "Collective Wisdom: The Future of Patient-Centered Care and Research" [PRESIDENTIAL ADDRESS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Vose Tags: Notes from the Editors PRESIDENTIAL ADDRESS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

ERRATA [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Tags: Errata Source Type: research

Reply to D. Vordermark and T. Pelz and R. Mazzola et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: van Nimwegen, Cutter, Schaapveld, Darby, Aleman, van Leeuwen Tags: CORRESPONDENCE Source Type: research

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Mazzola, Giaj Levra, Alongi Tags: CORRESPONDENCE Source Type: research

Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Vordermark, Pelz Tags: CORRESPONDENCE Source Type: research

Ensuring Transparency and Consistency in the Value Assessment of Cancer Therapies [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Iskrov, Stefanov Tags: CORRESPONDENCE Source Type: research

Comment on the American Society of Clinical Oncology Value Statement [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Weber, Drakeman Tags: CORRESPONDENCE Source Type: research

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Malone, Berg, Claxton, Garrison, IJzerman, Marsh, Neumann, Sculpher, Towse, Uyl-de Groot, Weinstein Tags: CORRESPONDENCE Source Type: research

Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Angelis, Kanavos Tags: CORRESPONDENCE Source Type: research

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received [ASCO SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Schnipper, Davidson, Wollins, Blayney, Dicker, Ganz, Hoverman, Langdon, Lyman, Meropol, Mulvey, Newcomer, Peppercorn, Polite, Raghavan, Rossi, Saltz, Schrag, Smith, Yu, Hudis, Vose, Schilsky Tags: Quality of Care, Cost of Cancer Care ASCO SPECIAL ARTICLE Source Type: research

Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up [Cancer Prevention and Control]
Conclusion Although telephone counseling led to lower testing uptake, our findings suggest that telephone counseling can be effectively used to increase reach and access without long-term adverse psychosocial consequences. Further work is needed to determine long-term adherence to risk management guidelines and effective strategies to boost utilization of primary and secondary preventive strategies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Kinney, Steffen, Brumbach, Kohlmann, Du, Lee, Gammon, Butler, Buys, Stroup, Campo, Flores, Mandelblatt, Schwartz Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Outcomes Research, Quality of Life Cancer Prevention and Control Source Type: research

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study [Gastrointestinal Cancer]
This study evaluated the 12-gene Recurrence Score assay for stage II and III colon cancer without chemotherapy to reveal the natural course of recurrence risk in stage III disease. Methods A cohort-sampling design was used. From 1,487 consecutive patients with stage II to III disease who had surgery alone, 630 patients were sampled for inclusion with a 1:2 ratio of recurrence and nonrecurrence. Sampling was stratified by stage (II v III). The assay was performed on formalin-fixed, paraffin-embedded primary cancer tissue. Association of the Recurrence Score result with recurrence-free interval (RFI) was assessed by using w...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Yamanaka, Oki, Yamazaki, Yamaguchi, Muro, Uetake, Sato, Nishina, Ikeda, Kato, Kanazawa, Kusumoto, Chao, Lopatin, Krishnakumar, Bailey, Akagi, Ochiai, Ohtsu, Ohashi, Yoshino Tags: Gastrointestinal Cancer Source Type: research

Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival [Gastrointestinal Cancer]
Purpose Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored. Patients and Methods We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient,
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Yuan, Qian, Babic, Morales-Oyarvide, Rubinson, Kraft, Ng, Bao, Giovannucci, Ogino, Stampfer, Gaziano, Sesso, Buring, Cochrane, Chlebowski, Snetselaar, Manson, Fuchs, Wolpin Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Gastrointestinal Cancer Source Type: research

Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium [Epidemiology]
Purpose An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3). Patients and Methods Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing-risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contrace...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Wentzensen, Poole, Trabert, White, Arslan, Patel, Setiawan, Visvanathan, Weiderpass, Adami, Black, Bernstein, Brinton, Buring, Butler, Chamosa, Clendenen, Dossus, Fortner, Gapstur, Gaudet, Gram, Hartge, Hoffman-Bolton, Idahl, Jones, Kaaks, Kirsh, Koh, Lac Tags: Cancer Etiology, Behavioral and Lifestyle Risk Factors, Epidemiology Source Type: research

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial [Gynecologic Cancer]
Conclusion No significant survival benefit was found for CPT-P. Both regimens were well tolerated, but the toxicity profiles differed significantly. Treatment with existing anticancer agents has limitations to improving the prognosis of CCC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Sugiyama, Okamoto, Enomoto, Hamano, Aotani, Terao, Suzuki, Mikami, Yaegashi, Kato, Yoshikawa, Yokoyama, Tanabe, Nishino, Nomura, Kim, Kim, Pignata, Alexandre, Green, Isonishi, Terauchi, Fujiwara, Aoki Tags: Chemotherapy Gynecologic Cancer Source Type: research

The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions [Clinical Practice]
Conclusion Oncologist implicit racial bias is negatively associated with oncologist communication, patients’ reactions to racially discordant oncology interactions, and patient perceptions of recommended treatments. These perceptions could subsequently directly affect patient-treatment decisions. Thus, implicit racial bias is a likely source of racial treatment disparities and must be addressed in oncology training and practice. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Penner, Dovidio, Gonzalez, Albrecht, Chapman, Foster, Harper, Hagiwara, Hamel, Shields, Gadgeel, Simon, Griggs, Eggly Tags: Quality of Care Clinical Practice Source Type: research

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [Thoracic Oncology]
Conclusion Consistent with its activity in ASCEND-1, ceritinib treatment provided clinically meaningful and durable responses with manageable tolerability in chemotherapy- and crizotinib-pretreated patients, including those with brain metastases. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Crino, Ahn, De Marinis, Groen, Wakelee, Hida, Mok, Spigel, Felip, Nishio, Scagliotti, Branle, Emeremni, Quadrigli, Zhang, Shaw Tags: Chemotherapy Thoracic Oncology Source Type: research

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 [Thoracic Oncology]
Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non–small-cell lung cancer. Patients and Methods Patients were randomly assigned to receive crizotinib (250 mg twice daily; n = 172) or chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin at area under the curve 5 to 6, every 3 weeks for ≤ six cycles; n = 171). Patients with stable treated brain metastases (tBM) were eligible. Intracranial efficacy was assessed at baseline and every 6 or 12 weeks in patients with or without known brain meta...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Solomon, Cappuzzo, Felip, Blackhall, Costa, Kim, Nakagawa, Wu, Mekhail, Paolini, Tursi, Usari, Wilner, Selaru, Mok Tags: Chemotherapy Thoracic Oncology Source Type: research

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [Hematologic Malignancy]
Purpose A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between 1973 and 2013 in Sweden. Materials and Methods Patients recorded as having CML in the Swedish Cancer Registry from 1973 to 2013 were included in the study and followed until death, censorship, or end of follow-up. The life expectancy and loss in expectation of life were predicted from a flexible parametric re...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Bower, Bjorkholm, Dickman, Hoglund, Lambert, Andersson Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Hematologic Malignancy Source Type: research

Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation [Hematologic Malignancy]
Conclusion Our findings suggest that the repeated infusion of MSCs might inhibit cGVHD symptoms in patients after HLA-haplo HSCT, accompanied by changes in the numbers and subtypes of T, B, and NK cells, leading to the acquisition of immune tolerance. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Gao, Zhang, Hu, Liu, Kong, Lou, Su, Yang, Li, Liu, Zhang, Gao, Zhu, Wen, Wang, Chen, Zhong, Zhang Tags: Leukemia, Combined Therapy, Biological Therapy Hematologic Malignancy Source Type: research

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer [Urologic Oncology]
Purpose There is growing interest in the role of local therapies, including external beam radiotherapy (RT), for men with metastatic prostate cancer (mPCa). We used the National Cancer Database (NCDB) to evaluate the overall survival (OS) of men with mPCa treated with androgen deprivation (ADT) with and without prostate RT. Methods The NCDB was queried for men with newly diagnosed mPCa, all treated with ADT, with complete datasets for RT, surgery, prostate-specific antigen (PSA) level, Gleason score, and Charlson-Deyo comorbidity score. OS was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Rusthoven, Jones, Flaig, Crawford, Koshy, Sher, Mahmood, Chen, Chapin, Kavanagh, Pugh Tags: Combined Modality Therapy Urologic Oncology Source Type: research

Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial [Breast Cancer]
Purpose The purpose of this randomized trial was to evaluate the efficacy of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR[BC]) program in improving psychological and physical symptoms and quality of life among breast cancer survivors (BCSs) who completed treatment. Outcomes were assessed immediately after 6 weeks of MBSR(BC) training and 6 weeks later to test efficacy over an extended timeframe. Patients and Methods A total of 322 BCSs were randomly assigned to either a 6-week MBSR(BC) program (n = 155) or a usual care group (n = 167). Psychological (depression, anxiety, stress, and fear of recurrence) a...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Lengacher, Reich, Paterson, Ramesar, Park, Alinat, Johnson-Mallard, Moscoso, Budhrani-Shani, Miladinovic, Jacobsen, Cox, Goodman, Kip Tags: Quality of Life, Pain Control Breast Cancer Source Type: research

Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer [Rapid Communication]
Conclusion Despite an unknown clinical benefit, approximately one third of elderly women with MBC were extreme users of disease-monitoring tests. Higher use of disease-monitoring tests was associated with higher total health care costs. Efforts to understand the optimal frequency of monitoring are needed to inform clinical practice. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Accordino, Wright, Vasan, Neugut, Hillyer, Hu, Hershman Tags: Epidemiology, Quality of Care, Rapid Communications Source Type: research

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 54-year-old man with a former 15-pack-year smoking history presents with cough and dyspnea. Initial wor...
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Rusthoven, Doebele Tags: Oncology Grand Rounds Source Type: research

Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Lazarus, Pavletic Tags: EDITORIALS Source Type: research

Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Logothetis, Aparicio Tags: Combined Modality Therapy EDITORIALS Source Type: research

Reining in the Excessive Use of Medical Tests: What Are the Next Steps? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Smith, Smith Tags: Chemotherapy, Cost Effectiveness, Quality of Care, Policy Analysis, Nuclear Medicine, CT EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Nead, Gaskin, Chester, Swisher-McClure, Dudley, Leeper, Shah Tags: CORRESPONDENCE Source Type: research

Androgen Deprivation Therapy and Risk of Alzheimers Disease: Importance of Holistic Geriatric Oncology Assessment [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Brady, OConnor, Power Tags: CORRESPONDENCE Source Type: research

Association of Androgen Deprivation Therapy With Alzheimers Disease: Unmeasured Confounders [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Leow, Cole, Sun, Trinh Tags: CORRESPONDENCE Source Type: research

Androgen Deprivation Therapy and Alzheimer's Disease [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Froehner, Wirth Tags: CORRESPONDENCE Source Type: research

Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Bowen, Butler, Atwood Tags: CORRESPONDENCE Source Type: research

Reply to Yang et al and De Bari et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Wahl, Tao, Schipper, Lawrence, Feng Tags: CORRESPONDENCE Source Type: research

Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: De Bari, Ozsahin, Bize, Boussaha, Deplanque, Wagner, Bourhis, Denys Tags: CORRESPONDENCE Source Type: research

Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Yang, Lo, Huang Tags: CORRESPONDENCE Source Type: research

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide evidence-based recommendations to oncologists and others for the treatment of patients with metastatic pancreatic cancer. Methods American Society of Clinical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology, palliative care, and advocacy experts to conduct a systematic review of the literature from April 2004 to June 2015. Outcomes were overall survival, disease-free survival, progression-free survival, and adverse events. Results Twenty-four randomized controlled trials met the systematic review criteria. Recommendations A multiphase comp...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Sohal, Mangu, Khorana, Shah, Philip, OReilly, Uronis, Ramanathan, Crane, Engebretson, Ruggiero, Copur, Lau, Urba, Laheru Tags: ASCO Guidelines, Diagnosis & Staging, Chemotherapy, Palliative Care ASCO SPECIAL ARTICLE Source Type: research

Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial [Palliative and Supportive Care]
Conclusion The lack of effectiveness of dietary restrictions and restrictions regarding social contacts and pets should result in reconsideration of anti-infective policies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Tramsen, Salzmann-Manrique, Bochennek, Klingebiel, Reinhardt, Creutzig, Sung, Lehrnbecher Tags: Supportive Care Palliative and Supportive Care Source Type: research

Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response [Palliative and Supportive Care]
Purpose Quality of life is a key component of cancer care; however, the factors that determine quality of life are not well understood. The aim of this study was to examine the relationship between quality of life parameters, performance status (PS), and the systemic inflammatory response in patients with advanced cancer. Methods An international biobank of patients with advanced cancer was analyzed. Quality of life was assessed at a single time point by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30). PS was assessed by using the Eastern Cooperative ...
Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Laird, Fallon, Hjermstad, Tuck, Kaasa, Klepstad, McMillan Tags: Bioinformatics, Population and observational studies (SEER, WHI observational, etc.), Quality of Life, Supportive Care Palliative and Supportive Care Source Type: research